1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Acne Pipeline Yields Three Disappointments, One Win So Far In 2017

 
• By Mandy Jackson

The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.

Acne on face

Allergan PLC and Paratek Pharmaceuticals Inc. had the only positive acne data out of four later-stage programs that have reported results so far in 2017 when the partners unveiled Phase III results for sarecycline, a potentially safer cycline oral antibiotic.

Allergan/Paratek, Xenon Pharmaceuticals Inc. and Foamix Pharmaceuticals Ltd. all reported acne clinical trial data in late March, but Xenon's Phase II and Foamix's Phase III trials for topical products failed or showed mixed results, following in the footsteps of disappointing Phase III data for Novan Inc.'s topical treatment in January

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas